Rituxan Rituximab - 100mg Vial for Intravenous Use

Rituxan Rituximab - 100mg Vial for Intravenous Use

<< >>
Usage conditions apply
Downloads
Description (Brief)
(From box) For single-use IV administration only.
(From insert)
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of patients with:
--Non-Hodgkin's Lymphoma
--Chronic Lymphocytic Leukemia
--Rheumatoid Arthritis in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies
-Wegener's Granulomatosis and Microscopic Polyangiitis in adult patients in combination with glucocorticoids
Location
Currently not on view
Object Name
pharmaceutical
biological
date made
ca 2013
product expiration date
2015-03
maker
Genentech, Inc.
place made
United States: California, South San Francisco
Physical Description
glass (overall material)
plastic (overall material)
cardboard (overall material)
metal (overall material)
rituximab, 100mg/10mL (overall ingredient)
Measurements
overall: 1 1/2 in x 2 3/4 in x 4 1/2 in; 3.81 cm x 6.985 cm x 11.43 cm
overall: 4 5/8 in x 2 3/4 in x 1 1/2 in; 11.7475 cm x 6.985 cm x 3.81 cm
ID Number
2013.0069.10
catalog number
2013.0069.10
accession number
2013.0069
Credit Line
Gift of Genentech, Inc.
See more items in
Medicine and Science: Medicine
Health & Medicine
The Antibody Initiative
Antibody Initiative: Monoclonal Antibodies
Data Source
National Museum of American History
Nominate this object for photography.   

Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.

If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.

Comments

Add a comment about this object